Azif decided to enter the medical insurance, exclusive interview with the real creature Liu Yong: did not consider too many interests

　　"The negotiations went well." January 7th was the third day of the national medical insurance negotiations.

At 6:45 that night, Liu Yong, executive vice president of Henan Real Biotechnology Co., Ltd., and two other colleagues walked out from the West Gate 2 of the National People's Congress Center. There were too many responses, and in the face of inquiries about the results of the negotiations, they just nodded with a smile.

　　On the evening of January 8, the National Medical Insurance Administration released a message. The person in charge of the Medical Management Department of the National Medical Insurance Administration introduced, "This year, there are a total of Azvudine tablets, Naimatevir tablets/Ritonavir tablets combined packaging, lung-clearing and detoxification The three new crown treatment drugs of granules participated in the negotiation through the procedures of self-declaration, formal review, and expert review. Among them, Azvudine Tablets and Qingfei Paidu Granules were negotiated successfully, but Paxlovid failed due to high quotations from the manufacturer Pfizer Investment Co., Ltd. success."

　　Faced with this result, a reporter from the People’s Daily Health client had an exclusive interview with Liu Yong, the vice president of Real Bio, “Actually, we are not under great pressure, because we have never put the interests of the company first in this medical insurance negotiation. More consideration is the accessibility of Azvudine and the fulfillment of corporate social responsibility."

　　"Although the pressure is not great, before participating in the medical insurance negotiation, we also conducted a strict drug evaluation, and fully communicated with many pharmacy experts and clinical experts, and invited professionals to help us conduct multiple rounds of counseling and rehearsal. and rehearsal, but when we arrived at the negotiation site, we found that they were useless.” Liu Yong said with a smile, the whole negotiation process was actually very fast. After our first round of quotations, experts said that there was still a big gap between the price and the reserve price. The round of quotations directly lowered the price, so the negotiation went smoothly.

　　Walking out of the negotiation site, when Liu Yong told us about this period of experience, it was a little calm, but the reporter could see that the other two experts who accompanied Liu Yong in the negotiation took a breath, "Actually, I heard that there is a big difference. At that time, I was really nervous." Liu Yong said frankly, so they walked out of the negotiation venue at the first time, called Wang Chaoyang, the founder of Real Bio, to report, and applied for and confirmed the specific amount of the second round of quotations.

　　"Reduce as soon as you need to, don't think too much about interests at this time." This is Wang Chaoyang's reply to them. Liu Yong said, in fact, generally speaking, we are willing to lower the price throughout the process, and we are fully prepared for the price reduction , The purpose of participating in the medical insurance negotiation is also to make this drug affordable for more Chinese people.

　　It is understood that Azvudine’s indications for the treatment of COVID-19 were only approved in July last year, and this national talk only involves the indications for the treatment of AIDS.

　　"Although we are here to talk about AIDS indications this time, because the drug involves the particularity of the new crown treatment, this pricing will also affect the pricing of the new crown treatment." Liu Yong introduced that in special periods, as long as the country needs it, as long as it is Accessible to patients, as long as the price is within the tolerance of the company, we are willing to give more benefits to our patients. We are always unwilling to pin the hopes of the elderly and high-risk groups in China on foreign medicines .

(Wang Aibing, Wang Zhenya/People's Daily Health Client)